Background: Extending the therapeutic window for thrombolysis is an important strategy in
maximizing the proportion of patients treated. ECASS III examined a 3–4.5-hour window and …

Summary Background In September, 2008, the European Acute Stroke Study III (ECASS III)
randomised trial and the Safe Implementation of Treatment in Stroke-International Stroke …

Background—The use of recombinant tissue plasminogen activator (rtPA) within 3 hours
after onset of an ischemic stroke is an established therapy. Because the use of intravenous …

BACKGROUND: Ischemic cerebrovascular accidents remain a leading cause of morbidity
and mortality. Thrombolytic therapy for acute ischemic stroke within 3h of symptom onset of …

Background and Purpose—Only a single study has demonstrated beneficial effects of
intravenous tissue plasminogen activator (tPA) in stroke patients. Methods—We evaluated …

Data from randomized clinical trials have supported the safety and efficacy of intravenous
tissue-type plasminogen activator (IV tPA) for acute ischemic stroke when administered …

Background: The safety of intravenous (IV) thrombolysis when administered between 4.5
and 6 h after acute ischemic stroke with alteplase has not been established. Purpose: The …

Importance Pooled analysis of randomized controlled trials of intravenous thrombolysis
shows no statistically significant benefit beyond 4.5 hours, with the possible advantage …

BACKGROUND: The administration of tissue plasminogen activator (t-PA) has been proven
effective for ischemic stroke within 3 h after onset. A pooled-analysis of six trials showed that …

Summary Background and Purpose The European Cooperative Acute Stroke Study
(ECASS) III showed that intravenous recombinant tissue plasminogen activator (rt PA) …